140 related articles for article (PubMed ID: 38363353)
1. Understanding the impact of non-alcoholic steatohepatitis with metabolic comorbidities on adults: a real-world qualitative study.
Shinde S; Taylor N; Chinthammit C; Wilson R; Burgess SM; Poon JL
Curr Med Res Opin; 2024 Apr; 40(4):665-676. PubMed ID: 38363353
[TBL] [Abstract][Full Text] [Related]
2. Understanding Patient Preferences and Unmet Needs in Non-alcoholic Steatohepatitis (NASH): Insights from a Qualitative Online Bulletin Board Study.
Cook NS; Nagar SH; Jain A; Balp MM; Mayländer M; Weiss O; Chatterjee S
Adv Ther; 2019 Feb; 36(2):478-491. PubMed ID: 30547371
[TBL] [Abstract][Full Text] [Related]
3. The burden of non-alcoholic steatohepatitis: A systematic review of health-related quality of life and patient-reported outcomes.
Younossi Z; Aggarwal P; Shrestha I; Fernandes J; Johansen P; Augusto M; Nair S
JHEP Rep; 2022 Sep; 4(9):100525. PubMed ID: 36039144
[TBL] [Abstract][Full Text] [Related]
4. A qualitative patient interview study to understand the experience of patients with nonalcoholic steatohepatitis.
Swain MG; Pettersson B; Meyers O; Venerus M; Oscarsson J
Hepatol Commun; 2023 Mar; 7(3):e0036. PubMed ID: 36757391
[TBL] [Abstract][Full Text] [Related]
5. Nonalcoholic steatohepatitis diagnosis and treatment from the perspective of patients and primary care physicians: a cross-sectional survey.
Nadolsky K; Cryer DR; Articolo A; Fisher T; Schneider J; Rinella M
Ann Med; 2023 Dec; 55(1):2211349. PubMed ID: 37171239
[TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics and management of patients with nonalcoholic steatohepatitis in a real-world setting: analysis of the Ipsos NASH therapy monitor database.
Shelley K; Articolo A; Luthra R; Charlton M
BMC Gastroenterol; 2023 May; 23(1):160. PubMed ID: 37208593
[TBL] [Abstract][Full Text] [Related]
7. Development of a Patient-Reported Outcome Measure for Non-Alcoholic Steatohepatitis (NASH-CHECK): Results of a Qualitative Study.
Doward LC; Balp MM; Twiss J; Slota C; Cryer D; Brass CA; Anstee QM; Sanyal AJ
Patient; 2021 Sep; 14(5):533-543. PubMed ID: 33336323
[TBL] [Abstract][Full Text] [Related]
8. Thematic analysis to explore patients' experiences with long COVID-19: a conceptual model of symptoms and impacts on daily lives.
Rofail D; Somersan-Karakaya S; Choi JY; Przydzial K; Zhao Y; Hussein M; Norton TD; Podolanczuk AJ; Mylonakis E; Geba GP
BMJ Open; 2024 Jan; 14(1):e076992. PubMed ID: 38233059
[TBL] [Abstract][Full Text] [Related]
9. Advanced fibrosis associated with non-alcoholic steatohepatitis (NASH) in Spain: results of a Delphi study.
Aller R; Calleja JL; Crespo J; Romero-Gómez M; Turnes J; Benmarzouk-Hidalgo OJ; Subirán R; Gil A
Gastroenterol Hepatol; 2024 Apr; 47(4):337-346. PubMed ID: 37343722
[TBL] [Abstract][Full Text] [Related]
10. Understanding the Symptom Burden and Impact of Myasthenia Gravis from the Patient's Perspective: A Qualitative Study.
Jackson K; Parthan A; Lauher-Charest M; Broderick L; Law N; Barnett C
Neurol Ther; 2023 Feb; 12(1):107-128. PubMed ID: 36322146
[TBL] [Abstract][Full Text] [Related]
11. Palliative care experiences of adult cancer patients from ethnocultural groups: a qualitative systematic review protocol.
Busolo D; Woodgate R
JBI Database System Rev Implement Rep; 2015 Jan; 13(1):99-111. PubMed ID: 26447011
[TBL] [Abstract][Full Text] [Related]
12. Qualitative interviews to improve patient-reported outcome measures in late-onset Pompe disease: the patient perspective.
Hamed A; An Haack K; Gwaltney C; Baranowski E; Stewart A; Krupnick R; Tyler M; Sparks S; Paty J
Orphanet J Rare Dis; 2021 Oct; 16(1):428. PubMed ID: 34641935
[TBL] [Abstract][Full Text] [Related]
13. A Structured Literature Review of the Epidemiology and Disease Burden of Non-Alcoholic Steatohepatitis (NASH).
Povsic M; Wong OY; Perry R; Bottomley J
Adv Ther; 2019 Jul; 36(7):1574-1594. PubMed ID: 31065991
[TBL] [Abstract][Full Text] [Related]
14. Health-related quality of life and patient-reported outcome measures in NASH-related cirrhosis.
McSweeney L; Breckons M; Fattakhova G; Oluboyede Y; Vale L; Ternent L; Balp MM; Doward L; Brass CA; Beyer F; Sanyal A; Anstee QM
JHEP Rep; 2020 Jun; 2(3):100099. PubMed ID: 32435754
[TBL] [Abstract][Full Text] [Related]
15. Evaluating the Relationship Between Metabolic Syndrome and Liver Biopsy-Proven Non-Alcoholic Steatohepatitis in China: A Multicenter Cross-Sectional Study Design.
Xu ZJ; Shi JP; Yu DR; Zhu LJ; Jia JD; Fan JG
Adv Ther; 2016 Nov; 33(11):2069-2081. PubMed ID: 27743352
[TBL] [Abstract][Full Text] [Related]
16. Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry.
Younossi ZM; Yilmaz Y; Yu ML; Wai-Sun Wong V; Fernandez MC; Isakov VA; Duseja AK; Mendez-Sanchez N; Eguchi Y; Bugianesi E; Burra P; George J; Fan JG; Papatheodoridis GV; Chan WK; Alswat K; Saeed HS; Singal AK; Romero-Gomez M; Gordon SC; Roberts SK; El Kassas M; Kugelmas M; Ong JP; Alqahtani S; Ziayee M; Lam B; Younossi I; Racila A; Henry L; Stepanova M;
Clin Gastroenterol Hepatol; 2022 Oct; 20(10):2296-2306.e6. PubMed ID: 34768009
[TBL] [Abstract][Full Text] [Related]
17. Patient-reported outcomes in patients with non-alcoholic fatty liver disease: A narrative review of Chronic Liver Disease Questionnaire-non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.
Yamamura S; Nakano D; Hashida R; Tsutsumi T; Kawaguchi T; Okada M; Isoda H; Takahashi H; Matsuse H; Eguchi Y; Sumida Y; Nakajima A; Gerber L; Younossi ZM; Torimura T
J Gastroenterol Hepatol; 2021 Mar; 36(3):629-636. PubMed ID: 32627871
[TBL] [Abstract][Full Text] [Related]
18. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis.
Quek J; Chan KE; Wong ZY; Tan C; Tan B; Lim WH; Tan DJH; Tang ASP; Tay P; Xiao J; Yong JN; Zeng RW; Chew NWS; Nah B; Kulkarni A; Siddiqui MS; Dan YY; Wong VW; Sanyal AJ; Noureddin M; Muthiah M; Ng CH
Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):20-30. PubMed ID: 36400097
[TBL] [Abstract][Full Text] [Related]
19. Real-world management of non-alcoholic steatohepatitis differs from clinical practice guideline recommendations and across regions.
Anstee QM; Hallsworth K; Lynch N; Hauvespre A; Mansour E; Kozma S; Marino JP; Bottomley J; Piercy J; Higgins V
JHEP Rep; 2022 Jan; 4(1):100411. PubMed ID: 34977520
[TBL] [Abstract][Full Text] [Related]
20. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.
Younossi ZM; Ratziu V; Loomba R; Rinella M; Anstee QM; Goodman Z; Bedossa P; Geier A; Beckebaum S; Newsome PN; Sheridan D; Sheikh MY; Trotter J; Knapple W; Lawitz E; Abdelmalek MF; Kowdley KV; Montano-Loza AJ; Boursier J; Mathurin P; Bugianesi E; Mazzella G; Olveira A; Cortez-Pinto H; Graupera I; Orr D; Gluud LL; Dufour JF; Shapiro D; Campagna J; Zaru L; MacConell L; Shringarpure R; Harrison S; Sanyal AJ;
Lancet; 2019 Dec; 394(10215):2184-2196. PubMed ID: 31813633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
